+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioavailability Enhancement Technologies and Services Market Industry Trends and Global Forecasts to 2035: By Type of Drug Class, Type of BCS Classification, Type of Bioavailability Enhancement Approach, Type of Dosage Form and Key Geographical Regions- Product Image
Bioavailability Enhancement Technologies and Services Market Industry Trends and Global Forecasts to 2035: By Type of Drug Class, Type of BCS Classification, Type of Bioavailability Enhancement Approach, Type of Dosage Form and Key Geographical Regions- Product Image
New

Bioavailability Enhancement Technologies and Services Market Industry Trends and Global Forecasts to 2035: By Type of Drug Class, Type of BCS Classification, Type of Bioavailability Enhancement Approach, Type of Dosage Form and Key Geographical Regions

  • PDF Icon

    Report

  • 270 Pages
  • March 2025
  • Region: Global
  • Roots Analysis
  • ID: 4575959
Description Jump to:

The global bioavailability enhancement technologies and services market is estimated to grow from USD 3.2 billion in 2025, to USD 10.22 billion by 2035, at a CAGR of 11.11% during the forecast period, to 2035.

Bioavailability Enhancement Technologies and Services Market: Growth and Trends

In recent years, the focus of drug developers has shifted towards development of lipophilic drug compounds due to the increasing issues with aqueous solubility of drugs. According to a recent study, around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability, the demand for novel bioavailability enhancement methods has grown significantly.

It is worth mentioning that since 2000, more than 55 players offering bioavailability enhancement technologies and services have been established. Amidst the growing competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor. This has led many service / technology providers to actively expand their portfolios, either through strategic acquisitions / mergers or entering into service alliances with other bioavailability enhancement companies. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace over the next decade.

Bioavailability Enhancement Technologies and Services Market: Key Insights

The report delves into the current state of the bioavailability enhancement technologies and services market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

  • Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles.

  • At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach.
  • Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers.
  • Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route.
  • A rise in partnerships focused on bioavailability enhancement services and technology platforms validates the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions.
  • In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions.
  • 5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby indicating the rapid pace of research activity within this domain.
  • Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio.
  • With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition.
  • Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future.
  • Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035.

Market Segmentation

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Drug Class

  • New Drug Approvals
  • Generics

Type of BCS Classification

  • BCS II Drugs
  • BCS IV Drugs

Type of Bioavailability Enhancement Approach

  • Solid Dispersion
  • Size Reduction
  • Lipid-based
  • Other Approaches

Type of Dosage Form

  • Liquids
  • Solids
  • Semi-Solids
  • Fine Particles

Key Geographical Regions

  • North America
  • Europe
  • Asia
  • Latin America
  • Middle East and North Africa
  • Rest of the World

Bioavailability Enhancement Technologies and Services Market: Key Segments

New Drug Approvals Occupy the Largest Share of the Bioavailability Enhancement Technologies and Services Market

Based on the type of drug class, the market is segmented into new drug approvals and generics. At present, new drug approvals hold the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the near future.

BCS II Drug Class is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of BCS classification, the market is segmented into BCS II drugs and BCS IV drugs. Currently, BCS II drug class holds the maximum share of the bioavailability enhancement technologies and services market. This trend is likely to remain the same in the coming decade.

Size Reduction Approach is the Fastest Growing Segment of the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of bioavailability enhancement approach, the market is segmented into solid dispersion, size reduction, lipid-based and other approaches. It is worth highlighting that, lipid-based approach holds a larger share of the bioavailability enhancement technologies and services market. However, the bioavailability enhancement technologies and services market for size reduction approach is likely to grow at a relatively higher CAGR.

Liquid Dosage Form is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market

Based on the type of dosage form, the market is segmented into liquids, solids, semi-solids and fine particles dosage form. Currently, liquid dosage form holds the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the foreseeable future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia is expected to grow at a higher CAGR.

Bioavailability Enhancement Technologies and Services Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bioavailability enhancement technologies and services market, focusing on key market segments, including type of drug class, type of BCS classification, type of bioavailability enhancement approach, type of dosage form, and key geographical regions.
  • Market Landscape 1: A comprehensive evaluation of bioavailability enhancement service providers, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported, bioavailability enhancement approach employed, type of dosage form supported, and route of administration of drug product.
  • Market Landscape 2: A comprehensive evaluation of bioavailability enhancement technology providers, considering various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, bioavailability enhancement principle supported, bioavailability enhancement approach employed, type of molecule, type of dosage form supported, route of administration,  availability for license and associated intellectual property rights.
  • Key Insights: A detailed analysis, encompassing the contemporary market trends, using six schematic representations, including a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered),  as well as a 3D bubble analysis comparing the key players engaged in drug bioavailability enhancement market, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).
  • Company Profiles: In-depth profiles of key industry players offering bioavailability enhancement technologies and services, focusing on company overviews, financial information (if available), bioavailability enhancement services portfolio, recent developments and an informed future outlook.
  • Competitive Benchmarking Analysis: A competitive benchmarking analysis that emphasizes the primary focus areas of various players engaged in the drug bioavailability enhancement market. This analysis compares their existing capabilities within and beyond their respective peer groups based in North America, Europe, Asia-Pacific, and other regions. It offers stakeholders insights into potential strategies for achieving a competitive edge in the industry.
  • Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.
  • Publication Analysis: A detailed review of peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as  year of publication, type of publication, popular keywords, top journals, top publishers and top copyright holders (in terms of number of articles published).
  • Patent Analysis: Detailed analysis of various patents filed / granted related to bioavailability enhancement approaches and technologies based on type of patent, patent application year, patent publication year, bioavailability enhancement approach, CPC symbols, geography, emerging focus area, type of organization, leading industry and non-industry players (in terms of number of patents filed/granted), and individual patent assignees (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various bioavailability enhancement of various drug compounds and / or candidates based on parameters like trial registration year, trial phase, current recruitment status, enrolled patient population, study design, type of sponsor / collaborator, leading industry and non-industry players (in terms of number of registered trials conducted), type of molecule and key geographies.
  • Technology Evaluation Framework: An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

Sample Players in the Bioavailability Enhancement Technologies and Services Market Profiled in the Report, Include:

  • Adare Pharma Solutions
  • Ascendia Pharmaceuticals
  • Catalent
  • Lonza
  • Lubrizol Life Science Health
  • Pace Life Sciences
  • Quotient Sciences
  • WuXi STA

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the factors that are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bioavailability Enhancement Technologies
3.3. Assessment of Drug Bioavailability
3.3.1. Key Considerations for Bioavailability and Assessment Studies
3.3.1.1. Absolute Bioavailability
3.3.1.2. Relative Bioavailability
3.3.1.3. Single and Multiple Dose Studies
3.3.2. Studies in Healthy Subjects and Patients
3.3.2.1. Different Bioavailability Assessment methods
3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
3.5.1. Drug Related Factors
3.5.2. Patient Physiology Related Factors
3.6. Bioavailability Enhancement Technologies
3.6.1. Physical Technologies for Bioavailability Enhancement
3.6.1.1. Solid Dispersion
3.6.1.1.1. Classification of Solid Dispersion Approaches
3.6.1.1.2. Methodologies for Solid Dispersion Approaches
3.6.1.1.2.1. Hot Melt Extrusion
3.6.1.1.2.2. Solvent Evaporation
3.6.1.1.2.3. Spray-Dried Dispersion
3.6.1.1.2.4. Other Techniques Used for Solid Dispersion
3.6.1.2. Nanosuspension Technology
3.6.1.2.1. Top-Down Approach
3.6.1.2.2. Bottom-Up Approach
3.6.2. Chemical Technologies for Bioavailability Enhancement
3.6.2.1. Lipid-Based Formulations
3.6.2.2. Non-Metal-Based Drug Delivery Systems
3.6.2.3. Polymer-Based Drug Delivery Systems
3.6.3. Biological Technologies for Bioavailability Enhancement
3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Bioavailability Enhancement Principle
4.2.5. Analysis by Bioavailability Enhancement Approach
4.2.5.1. Analysis by Solid Dispersion Approaches
4.2.5.2. Analysis by Size Reduction Approaches
4.2.5.3. Analysis by Lipid-Based Approaches
4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
4.2.6. Analysis by Dosage Form
4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
5.3.1. Analysis by Bioavailability Enhancement Principle
5.3.2. Analysis by Bioavailability Enhancement Approach
5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability EnhancementApproach
5.3.4. Analysis by Type of Molecule
5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
5.3.6. Analysis by Dosage Form
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Availability for License
5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS
6.1. Chapter Overview
6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Ascendia Pharmaceuticals
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. Catalent
7.4.1. Company Overview
7.4.2. Financial Overview
7.4.3. Recent Developments and Future Outlook
7.5. Lonza
7.5.1. Company Overview
7.5.2. Financial Overview
7.5.3. Recent Developments and Future Outlook
7.6. Lubrizol Life Science Health
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. Pace Life Sciences
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Quotient Sciences
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook
7.10. WuXi STA (A Subsidiary of WuXi AppTec)
7.10.1. Company Overview
7.10.2. Financial Overview
7.10.3. Recent Developments and Future Outlook

8. COMPANY BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
8.3.1. Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
8.3.3. Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
8.3.4. Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
8.3.6. Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post -2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
9.4.1. Analysis by Region
9.4.2. Analysis by Country
9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Bioavailability Enhancement Approach
10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach
10.3.5. Most Popular Journals: Analysis by Number of Publications
10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
10.3.7. Most Popular Publishers: Analysis by Number of Publications
10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
11.3.1. Analysis by Application Year
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Bioavailability Enhancement Approach
11.3.4. Analysis by CPC Symbols
11.3.5. Analysis by Geography
11.3.6. Analysis by Emerging Focus Areas
11.3.7. Analysis by Type of Organization
11.3.8. Leading Players: Analysis by Number of Patents
11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
12.3.1. Research Methodology
12.3.2. Analysis of Trials by Trial Registration Year
12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.4. Analysis of Trials by Study Design
12.3.5. Analysis of Trials by Trial Phase
12.3.6. Analysis of Trials by Trial Recruitment Status
12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
12.3.8. Analysis by Type of Molecule and Trial Phase
12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Study Focus
12.3.12. Analysis of Trials by Geography
12.3.13. Analysis of Enrolled Patient Population by Geography

13. TECHNOLOGY EVALUATION FRAMEWORK
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Technologies based on Solid Dispersion Approaches
13.3.1 List of Approved Drugs
13.3.2 Trends in Intellectual Capital
13.3.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.4. Technologies based on Size Reduction Approaches
13.4.1 List of Approved Drugs
13.4.2 Trends in Intellectual Property
13.4.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.5. Technologies based on Lipid-based Approaches
13.5.1 List of Approved Drugs
13.5.2 Trends in Intellectual Property
13.5.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.6. Technology Evaluation Framework: Wind Rose Representation
13.7. Technology Evaluation Framework: Spider Web Representation
13.8. Results and Discussions

14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035
14.4. Analysis by Drug Class, 2022 and 2035
14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035
14.4.2. Demand for Bioavailability Enhancement Technologies and Services forGenerics, 2022-2035
14.5. Analysis by BCS Classification, 2022 and 2035
14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS IIDrugs, 2022-2035
14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCSIV Drugs, 2022-2035
14.6. Analysis by Dosage Form, 2022 and 2035
14.6.1. Demand for Bioavailability Enhancement Technologies and Services forLiquids, 2022-2035
14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids,2022-2035
14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035
14.6.4. Demand for Bioavailability Enhancement Technologies and Services for FineParticles / Powders, 2022-2035
14.7. Concluding Remarks

15. MARKET FORECAST AND OPPURTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Bioavailability Enhancement Services Market, 2022-2035
15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035
15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035
15.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035
15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035
15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035
15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035
15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035
15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches,2022-2035
15.6.2. Bioavailability Enhancement Services Market for Solid DispersionApproaches, 2022-2035
15.6.3. Bioavailability Enhancement Services Market for Size Reduction Approaches,2022-2035
15.6.4. Bioavailability Enhancement Services Market for Other EnhancementApproaches, 2022-2035
15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035
15.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035
15.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035
15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035
15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders,2022-2035
15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035
15.8.  Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035
15.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035
15.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035
15.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035
15.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035
15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa,2022-2035
15.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035
15.9. Concluding Remarks

16. CONCLUSION17. APPENDIX I: LIST OF COMPANIES18. APPENDIX II: TABULATED DATA
LIST OF FIGURES
Figure 2.1 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Clinical Trial Analysis
Figure 2.7 Executive Summary: Demand Analysis
Figure 2.8 Executive Summary: Market Forecast
Figure 3.1 Bioavailability Enhancement Technologies: Historical Evolution of Bioavailability Enhancement Technologies
Figure 3.2 Single Dose Study: Drug Concentration-Time Curve
Figure 3.3 Multiple Dose Study: Drug Concentration-Time Curve
Figure 3.4 Different Bioavailability Assessment Methods
Figure 3.5 Biopharmaceutical Classification System
Figure 3.6 Factors Affecting Drug Bioavailability
Figure 3.7 Solid Dispersion Formulations: Classification
Figure 3.8 Solid Dispersion Formulations: Preparation Methodologies
Figure 3.9 Solid Dispersion Formulations: Melt Agglomeration Technique
Figure 3.10 Nanosuspension Formulations: Preparation Methodologies
Figure 3.11 Lipid-based Formulations: Classification
Figure 3.12 Biological Formulations: Classification
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 4.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 4.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 5.1 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Figure 5.2 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Figure 5.3 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.6 Leading Players: Distribution by Number of Technologies
Figure 5.7 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Figure 5.8 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Figure 5.9 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 5.10 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Figure 5.11 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Figure 5.12 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Figure 5.13 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Figure 5.14 Bioavailability Enhancement Technologies: Distribution by Availability for License
Figure 5.15 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Figure 6.1 Key Insights: Distribution by Company Size and Location of Headquarters
Figure 6.2 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Figure 6.3 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Figure 6.4 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Figure 6.5 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 6.6 Key Insights: Distribution by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region
Figure 7.1 Catalent: Annual Revenues, 2017-2022 (USD Billion)
Figure 7.2 Lonza: Annual Revenues, 2017-2022 H1 (CHF Billion)
Figure 7.3 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, 2017-2022 H1 (USD Billion)
Figure 8.1 Company Benchmarking Analysis: Distribution by Year of Establishment and Location of Headquarters
Figure 8.2 Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
Figure 8.3 Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
Figure 8.4 Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
Figure 8.5 Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
Figure 8.6 Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
Figure 8.7 Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
Figure 8.8 Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
Figure 8.9 Benchmarking of Players based in Asia and Rest of the World, Established Post-2000 (Peer Group VIII)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Figure 9.8 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Partner Headquarters
Figure 10.1 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Figure 10.4 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Figure 10.5 Most Popular Journals: Distribution by Number of Publications
Figure 10.6 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.7 Most Popular Publishers: Distribution by Number of Publications
Figure 10.8 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.9 Publication Analysis: Distribution by Popular Keywords
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Figure 11.3 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Figure 11.4 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents, Pre-2010 - 2022
Figure 11.5 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Figure 11.6 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Figure 11.7 Patent Analysis: Distribution by CPC Symbols
Figure 11.8 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 11.9 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 11.10 Patent Analysis: Distribution by Emerging Focus Area
Figure 11.11 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Figure 11.12 Leading Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.14 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.15 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 11.16 Patent Analysis: Distribution of Patents by Age (Pre-2010 - 2022)
Figure 11.17 Bioavailability Enhancement: Patent Valuation
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2022
Figure 12.3 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.4 Bioavailability Studies: Distribution of Trials by Study Design
Figure 12.5 Bioavailability Studies: Distribution of Trials by Trial Phase
Figure 12.6 Bioavailability Studies: Distribution of Trials by Recruitment Status
Figure 12.7 Bioavailability Studies: Distribution of Trials by Type of Sponsor / Collaborator
Figure 12.8 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Figure 12.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.11 Bioavailability Studies: Distribution by Study Focus
Figure 12.12 Bioavailability Studies: Geographical Distribution of Trials
Figure 12.13 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Figure 13.1 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.2 Technologies based on Lipid-based Approaches: Trends in Research Activity (Number of Publications)
Figure 13.3 Technologies Evaluation Framework: Lipid-based Approaches
Figure 13.4 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.5 Technologies based on Size Reduction Approaches: Trends in Research Activity (Number of Publications)
Figure 13.6 Technologies Evaluation Framework: Size Reduction Approaches
Figure 13.7 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.8 Technologies based on Solid Dispersion Approaches: Trend in Research Activity (Number of Publications)
Figure 13.9 Technologies Evaluation Framework: Solid Dispersion Approaches
Figure 13.10 Technologies based on Other Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.11 Technologies based on Other Approaches: Trends in Research Activity (Number of Publications)
Figure 13.12 Technologies Evaluation Framework: Other Approaches
Figure 13.13 Technology Evaluation Framework: Spider Web Representation
Figure 14.1 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Figure 14.2 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035
Figure 14.3 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035 (In Terms of Number of Projects)
Figure 14.4 Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035 (In Terms of Number of Projects)
Figure 14.5 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035
Figure 14.6 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 14.7 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 14.8 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035
Figure 14.9 Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035 (In Terms of Number of Projects)
Figure 14.10 Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035 (In Terms of Number of Projects)
Figure 14.11 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035 (In Terms of Number of Projects)
Figure 14.12 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035 (In Terms of Number of Projects)
Figure 15.1 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Billion)
Figure 15.2 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035
Figure 15.3 Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035 (USD Billion)
Figure 15.4 Bioavailability Enhancement Services Market for Generics, 2022-2035 (USD Billion)
Figure 15.5 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035
Figure 15.6 Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035 (USD Billion)
Figure 15.7 Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035 (USD Billion)
Figure 15.8 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035
Figure 15.9 Bioavailability Enhancement Services Market for Lipid-Based Approaches, 2022-2035 (USD Billion)
Figure 15.10 Bioavailability Enhancement Services Market for Size Reduction Approaches, 2022-2035 (USD Billion)
Figure 15.11 Bioavailability Enhancement Services Market for Solid Dispersion Approaches, 2022-2035 (USD Billion)
Figure 15.12 Bioavailability Enhancement Services Market for Other Approaches, 2022-2035 (USD Billion)
Figure 15.13 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035
Figure 15.14 Bioavailability Enhancement Services Market for Liquids, 2022-2035 (USD Billion)
Figure 15.15 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Billion)
Figure 15.16 Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035 (USD Billion)
Figure 15.17 Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035 (USD Billion)
Figure 15.18 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035
Figure 15.19 Bioavailability Enhancement Services Market in North America, 2022-2035 (USD Billion)
Figure 15.20 Bioavailability Enhancement Services Market in Europe, 2022-2035 (USD Billion)
Figure 15.21 Bioavailability Enhancement Services Market in Asia, 2022-2035 (USD Billion)
Figure 15.22 Bioavailability Enhancement Services Market in Latin America, 2022-2035 (USD Billion)
Figure 15.23 Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 15.24 Bioavailability Enhancement Services Market in Rest of the World, 2022-2035 (USD Billion)
Figure 15.25 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Billion)
Figure 16.1 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 16.2 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 16.3 Concluding Remarks: Partnerships and Collaborations
Figure 16.4 Concluding Remarks: Publication Analysis
Figure 16.5 Concluding Remarks: Patent Analysis
Figure 16.6 Concluding Remarks: Clinical Trial Analysis
Figure 16.7 Concluding Remarks: Demand Analysis
Figure 16.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 16.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

LIST OF TABLES
Table 4.1 List of Bioavailability Enhancement Service Providers
Table 4.2 Bioavailability Enhancement Service Providers: Information on BioavailabilityEnhancement Principle
Table 4.3 Bioavailability Enhancement Service Providers: Information on BioavailabilityEnhancement Approach
Table 4.4 Bioavailability Enhancement Service Providers: Information on Solid DispersionApproaches
Table 4.5 Bioavailability Enhancement Service Providers: Information on Size ReductionApproaches
Table 4.6 Bioavailability Enhancement Service Providers: Information on Lipid-BasedApproaches
Table 4.7 Bioavailability Enhancement Service Providers: Information on OtherBioavailability Enhancement Approaches
Table 4.8 Bioavailability Enhancement Service Providers: Information on Dosage Forms
Table 4.9 Bioavailability Enhancement Service Providers: Information on Routes ofAdministration
Table 5.1 List of Bioavailability Enhancement Technology Providers
Table 5.2 Bioavailability Enhancement Technologies: Information on BioavailabilityEnhancement Principles and Bioavailability Enhancement Approaches
Table 5.3 Bioavailability Enhancement Technologies: Information on Type of Molecule
Table 5.4 Bioavailability Enhancement Technologies: Information on Dosage Forms
Table 5.5 Bioavailability Enhancement Technologies: Information on Routes ofAdministration
Table 5.6 Bioavailability Enhancement Technologies: Information on Availability forLicense and Intellectual Property Rights
Table 7.1 List of Companies Profiled
Table 7.2 Adare Pharma Solutions: Company Snapshot
Table 7.3 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 7.4 Ascendia Pharmaceuticals: Company Snapshot
Table 7.5 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 7.6 Catalent: Company Snapshot
Table 7.7 Catalent: Recent Developments and Future Outlook
Table 7.8 Lonza: Company Snapshot
Table 7.9 Lonza: Recent Developments and Future Outlook
Table 7.10 Lubrizol Life Science Health: Company Snapshot
Table 7.11 Lubrizol Life Science Health: Recent Developments and Future Outlook
Table 7.12 Pace Life Sciences: Company Snapshot
Table 7.13 Pace Life Sciences: Recent Developments and Future Outlook
Table 7.14 Quotient Sciences: Company Snapshot
Table 7.15 Quotient Sciences: Recent Developments and Future Outlook
Table 7.16 WuXi STA (A Subsidiary of WuXi AppTec): Company Snapshot
Table 7.17 WuXi STA (A Subsidiary of WuXi AppTec): Recent Developments and FutureOutlook
Table 9.1 Bioavailability Enhancement: List of Partnerships and Collaborations, 2013-2022
Table 9.2 Bioavailability Enhancement Focused Partnerships and Collaborations:Information on Type of Agreement (Region-wise and Geography-wise)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 12.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 13.1 Technologies based on Lipid-based Approaches: List of Approved Drugs
Table 13.2 Technologies Based on Lipid-based Approaches: Global Competition
Table 13.3 Technologies based on Size Reduction Approaches: List of Approved Drugs
Table 13.4 Technologies Based on Size Reduction Approaches: Global Competition
Table 13.5 Technologies based on Solid Dispersion Approaches: List of Approved Drugs
Table 13.6 Technologies Based on Solid Dispersion Approaches: Global Competition
Table 13.7 Technologies based on Other Approaches: List of Approved Drugs
Table 13.8 Technologies Based on Other Approaches: Global Competition
Table 18.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 18.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 18.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Table 18.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 18.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 18.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Table 18.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 18.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 18.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Table 18.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 18.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 18.13 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Table 18.14 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Table 18.15 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 18.16 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.17 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Table 18.18 Leading Players: Distribution by Number of Technologies
Table 18.19 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Table 18.20 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Table 18.21 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.22 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Table 18.23 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Table 18.24 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Table 18.25 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Table 18.26 Bioavailability Enhancement Technologies: Distribution by Availability for License
Table 18.27 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Table 18.28 Key Insights: Distribution by Company Size and Location of Headquarters
Table 18.29 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Table 18.30 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Table 18.31 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Table 18.32 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.33 Catalent: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 18.34 Lonza: Annual Revenues, FY 2017-HI FY 2022 (CHF Billion)
Table 18.35 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, FY 2017- H1 FY 2022 (USD Billion)
Table 18.36 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Table 18.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.41 Most Active Players: Distribution by Number of Partnerships
Table 18.42 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Table 18.43 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 18.44 Partnerships and Collaboration: Distribution by Type of Partnership and Location of Partner Headquarters
Table 18.45 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Table 18.46 Publication Analysis: Distribution by Type of Publication
Table 18.47 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.48 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Table 18.49 Most Popular Journals: Distribution by Number of Publications
Table 18.50 Most Popular Journals: Distribution by Journal Impact Factor
Table 18.51 Most Popular Publishers: Distribution by Number of Publications
Table 18.52 Most Popular Copyright Holders: Distribution by Number of Publications
Table 18.53 Patent Analysis: Distribution by Type of Patent
Table 18.54 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Table 18.55 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Table 18.56 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications and Number of Granted Patents, Pre-2010-2022
Table 18.57 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.58 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Table 18.59 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 18.60 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 18.61 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Table 18.62 Leading Industry Players: Distribution by Number of Patents
Table 18.63 Leading Non-Industry Players: Distribution by Number of Patents
Table 18.64 Leading Patent Assignees: Distribution by Number of Patents
Table 18.65 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 18.66 Patent Analysis: Distribution of Patents by Age (pre-2010-2022)
Table 18.67 Bioavailability Enhancement: Patent Valuation
Table 18.68 Leading Patents: Distribution by Number of Citations
Table 18.69 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 18.70 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.71 Bioavailability Studies: Distribution of Trials by Study Design
Table 18.72 Bioavailability Studies: Distribution of Trials by Trial Phase
Table 18.73 Bioavailability Studies: Distribution of Trials by Recruitment Status
Table 18.74 Bioavailability Studies: Distribution of Trials by Type of Sponsor /Collaborator
Table 18.75 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Table 18.76 Leading Industry Players: Distribution by Number of Registered Trials
Table 18.77 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 18.78 Bioavailability Studies: Geographical Distribution of Trials
Table 18.79 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Table 18.80 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Table 18.81 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035 (In Terms of Number of Projects)
Table 18.82 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035 (In Terms of Number of Projects)
Table 18.83 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035 (In Terms of Number of Projects)
Table 18.84 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Million)
Table 18.85 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035 (USD Million)
Table 18.86 Bioavailability Enhancement Services Market for New Drug Approvals, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.87 Bioavailability Enhancement Services Market for Generics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.88 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035 (USD Million)
Table 18.89 Bioavailability Enhancement Services Market for BCS II Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.90 Bioavailability Enhancement Services Market for BCS IV Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.91 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035 (USD Million)
Table 18.92 Bioavailability Enhancement Services Market for Lipid Based Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.93 Bioavailability Enhancement Services Market for Solid Dispersion Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.94 Bioavailability Enhancement Services Market for Size Reduction Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.95 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.96 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035 (USD Million)
Table 18.97 Bioavailability Enhancement Services Market for Liquids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.98 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Million)
Table 18.99 Bioavailability Enhancement Services Market for Semi-Solids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.100 Bioavailability Enhancement Services Market for Fine Particles / Powders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.101 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035 (USD Million)
Table 18.102 Bioavailability Enhancement Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.103 Bioavailability Enhancement Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.104 Bioavailability Enhancement Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.105 Bioavailability Enhancement Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.106 Bioavailability Enhancement Services Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.107 Bioavailability Enhancement Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

Executive Summary

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:


  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the bioavailability enhancement technologies and services market in the short-mid and long term.

Chapter 3 is a general introduction to bioavailability. In this section, we have discussed, in detail, the concept of bioavailability and the current problems associated with bioavailability across various drug compounds. The chapter also features a detailed discussion on the current approaches being used for bioavailability enhancement.

Chapter 4 provides a comprehensive review of the global landscape of bioavailability enhancement technologies and service providers. It includes information related to over 150 companies that are currently operating in this domain. It features an in-depth market review, including a study of the regional distribution of players, analysis by company size and year of establishment, approach adopted for bioavailability enhancement, type of drug dosage form, route of administration, and the location of the company.

Chapter 5 features detailed profiles of some of the key players that are active in this domain and offer a wide range of services. Each profile presents an overview of the company, its financial information (if available), details related to its service(s) portfolio, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

Chapter 6 presents a benchmark analysis of all the players engaged in this domain. It highlights the capabilities of these companies in terms of their expertise across bioavailability enhancement. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.

Chapter 7 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this domain. In addition, we have highlighted the key players, on the basis of the number of collaborations and also discussed the expansion of services (via acquisitions / mergers) by key players.

Chapter 8 provides a comprehensive publication analysis, highlighting the recent trends in published literature related to bioavailability enhancement technologies. It presents a relative comparison of key technologies, on the basis of the trend in number of publications (CAGR) and the impact factors of the journals wherein these articles were published.

Chapter 9 provides detailed analysis of the patents that have recently been filed related to bioavailability enhancement technologies. The study also highlights the upcoming trends in innovation in this domain. In addition, it presents a high-level view on the valuation of these patents

Chapter 10 features an overview of the various ongoing clinical studies that are evaluating the bioavailability of various drug candidates that are currently under development. The chapter features a comprehensive view on the focus areas of these clinical studies, highlighting the key players involved as well.

Chapter 11 presents a detailed estimation of the likely demand for bioavailability enhancement technologies / services. It provides a comprehensive view in terms of the annual number of projects that are likely to require bioavailability enhancement in the period 2018-2030.

Chapter 12 provides a comprehensive market forecast analysis, highlighting the future potential of contract services for bioavailability enhancement till the year 2030. It features the likely distribution of the market based on [A] approach used for bioavailability enhancement (solid dispersion, size reduction, lipid-based approaches, and other approaches), [B] region (North America, Europe, Asia-Pacific and rest of the world), and [C] opportunity from drugs across different BCS classifications (BCS II and BCS IV).

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of this market in the foreseen future.

Chapter 14 is a collection of transcripts of the discussions by various stakeholders across the public domain.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adare Pharma Solutions
  • Ascendia Pharmaceuticals
  • Catalent
  • Lonza
  • Lubrizol Life Science Health
  • Pace Life Sciences
  • Quotient Sciences
  • WuXi STA

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Bioavailability Enhancement Technologies & Services Market by Technology Type, Service Type, Drug Type, Route Of Administration, End User - Global Forecast to 2030 - Product Image

Bioavailability Enhancement Technologies & Services Market by Technology Type, Service Type, Drug Type, Route Of Administration, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Long-Acting Drug Delivery Technologies and Services Market: Focus on Technology, Dosage Form, Type of Molecule Delivered, Material, Distribution Channel, and Region - Analysis and Forecast, 2025-2035 - Product Image

Long-Acting Drug Delivery Technologies and Services Market: Focus on Technology, Dosage Form, Type of Molecule Delivered, Material, Distribution Channel, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 90 Pages
  • Global
From
Bioanalytical Testing Services in CRO Market Size, Share & Trends Analysis Report by Molecule (Small, Large), Test (Bioavailability, Bioequivalence), Test, Workflow, End-Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Bioanalytical Testing Services in CRO Market Size, Share & Trends Analysis Report by Molecule (Small, Large), Test (Bioavailability, Bioequivalence), Test, Workflow, End-Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 180 Pages
  • Global
From
Oral Solid Dosage Forms (OSDF) and Pharma Excipients - Global Strategic Business Report - Product Image

Oral Solid Dosage Forms (OSDF) and Pharma Excipients - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Motion Sickness Treatment Market by Type Of Drugs, Treatment Type, Dosage Forms, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Motion Sickness Treatment Market by Type Of Drugs, Treatment Type, Dosage Forms, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From

About the Bioavailability Enhancement Market

Bioavailability Enhancement is a process used in pharmaceutical manufacturing to improve the absorption of a drug into the body. This is done by altering the drug's physical or chemical properties, such as its solubility, dissolution rate, or permeability. This can be achieved through various techniques, such as particle size reduction, salt formation, and prodrug design. Bioavailability Enhancement can improve the efficacy of a drug, reduce its side effects, and increase its shelf life. Companies in the Bioavailability Enhancement market include BASF, Merck, Pfizer, Novartis, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.